Minapharm’s standalone loss falls 5.1% YoY in 9 months
Updated 11/14/2022 3:00:00 PM
Arab Finance: Minapharm Pharmaceuticals (Minapharm) (MIPH) posted a 5.11% year-on-year (YoY) decrease in standalone net loss after tax in the first nine months of 2022, according to the standalone financial statement filed to the Egyptian Exchange (EGX) on November 14th.
Net loss after tax reached EGP 214.09 million in the January-September period of 2022, compared to EGP 225.63 million in the year-ago period.
It is worth noting that the company’s consolidated profits attributable to the parent company reached EGP 264.81 million in H1 2022, up from EGP 255.358 million in H1 2021.
Minapharm Pharmaceuticals is an Egypt-based company engaged in the production and distribution of pharmaceutical products. It distributes its products within and outside Egypt.
